GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.

Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of $0.39 and adjusted diluted EPS of $0.61 Net sales of $525 million CER ahead of outlook for ...

A recent survey commissioned by AARP Research revealed that a large majority of Connecticut residents support the ...

QIAGEN N.V.’s QGEN fourth-quarter 2024 adjusted earnings per share (EPS) were 61 cents, the same at the constant exchange rate (CER). The reported figure increased 11% from the 2023 comparable figure.

Fourth, in our sample ... gross margin improved to 67.1% of sales from 65.7% in Q4 2023, an increase of 1.4 percentage points and the key driver for the overall gain in adjusted operating income ...

The research finds, further, that the lower financial misconduct for local CEOs is not related to CEO compensation structures ...

Q4 sales & FY 2024 resultsSales & Ebita margin in line with revised guidance 2024; FCF conversion exceeding objective Positive North ...

Q1 2025 Earnings Call Transcript February 4, 2025 The AZEK Company Inc. beats earnings expectations. Reported EPS is $0.17, expectations were $0.14. Operator: Welcome to The AZEK Company’s First ...

We saw robust growth in website sessions, contractor leads, and sample ... gross profit was $104 million, an increase of $13 million year-over-year and gross margin was 36.3%. First quarter ...

To be eligible to contribute the maximum amount in 2025, your modified adjusted gross ... revert to 2017 income tax rates beginning January 1, 2026. If that happens, here’s a sample of what ...